8-K: Simulations Plus Reports 8% Revenue Growth in Q2 FY26

Simulations Plus announced its second quarter fiscal 2026 financial results, reporting an 8% increase in total revenue to $24.3 million, driven by growth in both software and services.

Summary

• Simulations Plus reported financial results for the second quarter ended February 28, 2026.
• Total revenue increased by 8% to $24.3 million compared to the prior year's second quarter.
• Software revenue grew by 9% to $14.6 million, making up 60% of total revenue.
• Services revenue increased by 8% to $9.7 million, representing 40% of total revenue.
• Gross profit reached $16.1 million with a gross margin of 66%.
• Net income was $4.5 million, or $0.22 per diluted share, up from $3.1 million, or $0.15 per diluted share, in the prior year.
• Adjusted EBITDA was $8.7 million, a 36% margin, compared to $6.6 million (29% margin) in the prior year.
• Adjusted net income was $7.0 million, or $0.35 per diluted share, compared to $6.2 million, or $0.31 per diluted share, in the prior year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report with solid revenue growth and improved profitability margins, though the EPS guidance adjustment due to tax rates tempers the overall outlook slightly.

Positives

• Total revenue increased by 8% to $24.3 million in Q2 FY26.
• Software revenue grew by 9% to $14.6 million.
• Services revenue grew by 8% to $9.7 million.
• Gross profit increased to $16.1 million with a gross margin of 66%, up from 59% in Q2 FY25.
• Net income rose to $4.5 million, with diluted EPS increasing to $0.22 from $0.15.
• Adjusted EBITDA increased to $8.7 million, representing 36% of revenue, up from 29% in Q2 FY25.
• Adjusted diluted EPS improved to $0.35 from $0.31.
• Backlog increased by approximately 18% due to strong services bookings.

Negatives

• Software revenue for the first six months of fiscal 2026 decreased by 3% to $23.5 million.
• The company is adjusting its fiscal 2026 guidance range for adjusted diluted EPS from $1.03 - $1.10 to $0.75 - $0.85 due to an increased expected effective tax rate.

Risks

• Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially.
• Risks include the effectiveness of the company's operational structure.
• Ability to maintain competitive advantages and commercialize AI and cloud-enabled solutions.
• Evolving regulatory and data privacy standards governing AI technologies.
• Acceptance of new software and improved versions by customers.
• General economics of the pharmaceutical industry.
• Ability to finance growth and attract/retain qualified technical staff.
• Market conditions, macroeconomic factors, and sustainability of the market.

Future Outlook

The company is adjusting its fiscal 2026 guidance for adjusted diluted EPS to a range of $0.75 - $0.85, down from $1.03 - $1.10, due to an increase in the expected effective tax rate from 12-14% to 23-25%. Other previously issued guidance metrics remain unchanged, including projected revenue of $79M - $82M and an adjusted EBITDA margin of 26% - 30%.

Management Comments

• "We delivered solid second quarter results, with revenue increasing by 8%," said Shawn OConnor, CEO of Simulations Plus.
• "Software growth was driven by strong performance in discovery and development solutions, partially offset by an anticipated decline in clinical operations software."
• "We also saw continued success with new logo additions and client upsells."
• "Services revenue growth was primarily driven by development solutions and bookings were strong during the quarter, resulting in an approximately 18% increase in backlog."
• "Market conditions remain favorable. Globally, ongoing most-favored-nation pricing agreements, reduced tariff threats, and an improving funding environment are benefiting our clients."
• "In addition, we believe recent supplemental guidance on new approach methodologies is supporting increased client activity."
• "We are seeing this reflected in strong software renewals, logo activity, and services bookings."
• "Overall, we are pleased with our first half fiscal 2026 performance and encouraged by the momentum we see across the business," concluded OConnor.

Industry Context

StockSavvy.ai notes that Simulations Plus's results align with a broader trend in the biopharmaceutical industry towards leveraging AI and model-informed approaches to accelerate drug development, driven by favorable market conditions and regulatory guidance on new methodologies.

Comparison to Industry Standards

• No specific comparable companies or projects were mentioned in the filing for direct comparison of results.
• The filing discusses general market conditions and client activity, suggesting a favorable environment for companies in the drug development software and services sector.

Stakeholder Impact

• Shareholders: Potential for increased returns due to revenue growth and improved profitability, offset by reduced EPS guidance.
• Employees: Continued focus on attracting and retaining qualified technical staff is implied.
• Customers: Benefit from advanced drug development solutions, with potential for increased client activity.
• Suppliers/Creditors: No direct impact mentioned, but stable financial performance supports ongoing business relationships.

Next Steps

• Continue to monitor software renewals and client upsells.
• Focus on growth in discovery and development solutions.
• Manage the impact of anticipated decline in clinical operations software.
• Execute on long-term strategic vision, including AI and cloud-enabled solutions.

Key Dates

Recommendation

The company demonstrates consistent revenue growth and improved operational margins, which is positive. However, the significant downward revision of the full-year EPS guidance due to a higher tax rate introduces uncertainty and warrants a cautious 'hold' stance until the impact of the tax change is fully understood and future performance can be re-evaluated against the new guidance.

Keywords

Simulations Plus, 8-K, Financial Results, Drug Development Software, AI, Biopharma, Revenue Growth, Q2 FY26